Form 4 for ATYR aTYR PHARMA INC
Accepted 2023-12-12 00:00:00 ET · period of report 2023-12-11 · accession 0001209191-23-058377 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-12-12 | 2023-12-11+ | ATYR | Shukla Sanjay | Pres, CEO, Dir | P - Purchase | $1.18 | +15.0K | 94.2K | +19% | +$17.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-12 | P | A | 12,000 | $1.18 | 106,173 | D | — | — | (F1) Represents weighted average price for the shares. The shares were purchased at prices ranging from $1.175 to $1.18 per share. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price. |
| 2 | Common | Common Stock | 2023-12-11 | P | A | 3,000 | $1.17 | 94,173 | D | — | — |